DIAMIR BIOSCIENCES

DIAMIR BIOSCIENCES CORP. was founded in 2009, with its headquarters located in Monmouth Junction, New Jersey, USA. The company conducts all its operations through its wholly-owned subsidiary, DiamiR, LLC. DIAMIR BIOSCIENCES' mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for the early detection and monitoring of brain and synaptic health, including mild cognitive impairment and Alzheimer's disease, to enable earlier intervention and better care planning. The proprietary technology developed by DIAMIR BIOSCIENCES is based on the quantitative analysis of circulating organ-enriched microRNAs (miRNAs) in plasma, which are a different class of molecules from proteins; thus, this method tests a biological pathway distinct from traditional blood protein biomarkers. This technology can also be applied to disease areas beyond neurodegenerative diseases, including the rare neurological and developmental disorder Rett syndrome, cancer, and inflammatory diseases, although the company’s work in these areas is still in the early stages.